Edgar Filing: SKYEPHARMA PLC - Form 6-K

SKYEPHARMA PLC Form 6-K November 17, 2003

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a - 16 OR 15d - 16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2003

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

For Immediate Release

17 November 2003

Edgar Filing: SKYEPHARMA PLC - Form 6-K

SkyePharma PLC ("the Company")

Notification of Major Interest in Shares

In accordance with Part VI of the Companies Act 1985 (as amended) the Company was informed today that on 14 November 2003 Standard Life Investments, on behalf of the Standard Life Group, purchased 2,000,000 SkyePharma plc Ordinary Shares, thus increasing their holding to 26,230,736 Ordinary Shares, representing 4.25% of the issued share capital of the Company. These Ordinary Shares are registered in the name of Stanlife Nominees Limited.

- e n d s -

END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill Title: Company Secretary

Date: November 17, 2003